Challenges of diagnostic genomics in Latin America
Por:
Alvarez-Gomez R.M., De la Fuente-Hernandez M.A., Herrera-Montalvo, Luis, Hidalgo-Miranda, Alfredo
Publicada:
1 feb 2021
Resumen:
Cancer genome sequencing methods have now become essential for
diagnostic purposes, for devising treatment strategies, and for
monitoring disease regression and progression. However, access to these
benefits has not permeated homogeneously throughout the world; certain
regions, such as Latin America, have been slower at adopting these
technologies in terms of their routine use, development and patient
access. There are also differences among Latin American subregions with
respect to their prioritized types of neoplasia and the drugs that are
available and approved in them. An overview of the current situation,
including the status of genomics for cancer diagnostics and efforts by
type of cancer is presented. In addition, we discuss the perspective of
initiatives, alliances, and educational/research programs that pledge to
make cancer genomics diagnosis a reality for Latin American individuals'
health.
Filiaciones:
Alvarez-Gomez R.M.:
National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico
National Cancer Institute, San Fernando 22, Seccion XVI, Tlalpan, Mexico City, Mexico
De la Fuente-Hernandez M.A.:
National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico
Doctoral Program in Biological Sciences, National Autonomous University of Mexico, C.U., Coyoacan, Mexico City, 04510, Mexico
Herrera-Montalvo, Luis:
National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico
Hidalgo-Miranda, Alfredo:
National Institute of Genomic Medicine, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City, 14610, Mexico
|